Independent fund research. Built on SEC filings.

How we research funds

Fund comparison

XLV vs. GGHCX: which is better?

Bottom line

XLV vs GGHCX: the short answer

XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and GGHCX (INVESCO Health Care Fund) share a meaningful slice of their top holdings — about 55% by weight.

XLV is cheaper at 0.08% vs 1.07% — a difference of $99 a year per $10,000 invested.

Over five years, XLV returned +8.1% a year vs +2.6% for GGHCX.

GGHCX has a front-end sales load of up to 5.5%; the other does not.

Updated Nov 19, 2026

XLV vs GGHCX side by side

XLVGGHCX
TypeETFMutual fund
Fund familySPDR (State Street)Invesco
CategoryHealth Care SectorHealth Care Sector
Expense ratio0.08%1.07%
Annual cost per $10k$8$107
10-yr cost on $10k (prospectus)$103$1,784
Max front loadNone5.5%
12b-1 fee0.02%0.25%
1-yr return+14.5%+9.2%
5-yr return (annualized)+8.1%+2.6%
10-yr return (annualized)+9.8%+5.8%
Best quarter+14.5%+19.6%
Worst quarter−12.7%−16.5%
Net assets (fund)$40.6B$1.2B
Number of holdings6582
Portfolio turnover2%59%
Returns as ofDec 31, 2025Dec 31, 2025

Source: SEC Form N-PORT and fund prospectuses

Year-by-year returns

YearXLVGGHCXDifference
2025+14.5%+15.5%−1.0%
2024+2.5%+4.0%−1.5%
2023+2.0%+3.1%−1.1%
2022−2.1%−13.5%+11.5%
2021+25.9%+12.2%+13.7%
2020+13.3%+14.5%−1.2%
2019+20.7%+32.0%−11.3%
2018+6.3%+0.5%+5.8%
2017+21.7%+15.5%+6.2%
2016−2.8%−11.7%+8.9%

Source: Fund prospectus bar charts

Holdings overlap

10 of XLV's top 25 holdings also appear in GGHCX's top 25.

Shared top holdings
HoldingXLVGGHCX
Eli Lilly & Co16.51%10.59%
Johnson & Johnson10.64%6.76%
AbbVie Inc7.74%4.03%
UnitedHealth Group Inc6.57%6.17%
Merck & Co Inc5.52%4.59%
Thermo Fisher Scientific Inc3.24%1.55%
Gilead Sciences Inc2.73%3.63%
CVS Health Corp2.30%2.52%
Vertex Pharmaceuticals Inc2.19%2.01%
Cardinal Health Inc0.97%2.10%

Source: SEC Form N-PORT

XLV top 10

  1. Eli Lilly & Co — 16.51%
  2. Johnson & Johnson — 10.64%
  3. AbbVie Inc — 7.74%
  4. UnitedHealth Group Inc — 6.57%
  5. Merck & Co Inc — 5.52%
  6. Amgen Inc — 3.40%
  7. Thermo Fisher Scientific Inc — 3.24%
  8. Abbott Laboratories — 2.75%
  9. Gilead Sciences Inc — 2.73%
  10. Intuitive Surgical Inc — 2.45%

GGHCX top 10

  1. Eli Lilly and Co. — 10.59%
  2. Johnson & Johnson — 6.76%
  3. UnitedHealth Group Inc. — 6.17%
  4. Invesco Private Prime Fund — 4.67%
  5. Merck & Co., Inc. — 4.59%
  6. AbbVie Inc. — 4.03%
  7. Gilead Sciences, Inc. — 3.63%
  8. argenx SE — 3.24%
  9. CVS Health Corp. — 2.52%
  10. Welltower Inc. — 2.34%

FAQ

What is the difference between XLV and GGHCX?
XLV (State Street(R) Health Care Select Sector SPDR(R) ETF) and GGHCX (INVESCO Health Care Fund) share a meaningful slice of their top holdings — about 55% by weight. XLV is cheaper at 0.08% vs 1.07% — a difference of $99 a year per $10,000 invested.
Which is cheaper, XLV or GGHCX?
XLV has the lower expense ratio (0.08%).
Should I own both XLV and GGHCX?
Because their portfolios differ, owning both can add diversification — check how they fit your overall allocation.

Educational comparison based on public filings; not investment advice. Past performance does not guarantee future results.